WO1998043071A1 - Method and apparatus for arbitrating to obtain best estimates for blood constituent values and rejecting harmonics - Google Patents

Method and apparatus for arbitrating to obtain best estimates for blood constituent values and rejecting harmonics Download PDF

Info

Publication number
WO1998043071A1
WO1998043071A1 PCT/IB1997/000292 IB9700292W WO9843071A1 WO 1998043071 A1 WO1998043071 A1 WO 1998043071A1 IB 9700292 W IB9700292 W IB 9700292W WO 9843071 A1 WO9843071 A1 WO 9843071A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood constituent
pulse rate
pulse
confidence levels
data
Prior art date
Application number
PCT/IB1997/000292
Other languages
French (fr)
Inventor
Clark R. Baker, Jr.
Thomas J. Yorkey
Original Assignee
Nellcor Puritan Bennett Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nellcor Puritan Bennett Inc. filed Critical Nellcor Puritan Bennett Inc.
Priority to EP97906323A priority Critical patent/EP0966665A1/en
Priority to CA002283860A priority patent/CA2283860A1/en
Priority to AU21052/97A priority patent/AU736060B2/en
Priority to PCT/IB1997/000292 priority patent/WO1998043071A1/en
Priority to JP54325698A priority patent/JP2001517128A/en
Publication of WO1998043071A1 publication Critical patent/WO1998043071A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/27—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection ; circuits for computing concentration
    • G01N21/274—Calibration, base line adjustment, drift correction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/314—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths
    • G01N21/3151—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths using two sources of radiation of different wavelengths

Definitions

  • This invention relates to a method and apparatus for measuring physiological parameters, in particular for processing data so that its reliability can be assessed. It relates in particular to a method and apparatus for arbitrating to obtain best estimates for blood constituent values and rejecting harmonics.
  • Pulse oximeters typically measure and display various blood flow characteristics including the oxygen saturation of haemoglobin in arterial blood and pulse rate. Oximeters pass light through blood perfused tissue such as a finger or an ear, and photoelectrically sense the absorption of light in the tissue. The amount of light absorbed is then used to calculate the amount of the blood constituent (for example oxyhaemo- globin) being measured.
  • the present invention provides a technique for assessing signals relating to physiological parameters, in particular blood oxygen saturation and pulse rate, to determine whether and how they are to be displayed.
  • the signals can be derived using techniques of the type that are disclosed in the specifications of the three applications referred to above.
  • the technique of the invention involves arbitrating between possible values of the parameter in question according to a confidence level associated with each value based in a quality metric .
  • the invention provides a method of measuring a blood constituent value (for example, oxygenated haemoglobin in blood) using data comprising a single data set, which comprises :
  • the invention provides apparatus for measuring a blood constituent using a single data set, by applying the method referred to above.
  • the invention provides a method of determining a patient's pulse rate using data comprising a single data set corresponding to electromagnetic energy transmitted through the tissue of a patient, the method comprising the steps of :
  • the invention provides apparatus for determining a patient's pulse rate using a single data set, by applying the method referred to above .
  • the arbitrating step comprises:
  • the arbitrating step comprises linearly interpolating between the plurality of possible values to generate the measure of the blood constituent or the patient's pulse rate (as the case may be) where none of the confidence levels is greater than all other confidence levels by more than a first amount .
  • the quality metric is selected from the group comprising age of the possible blood constituent value and variance of the possible blood constituent value.
  • the pulse rate estimator determines its corresponding possible pulse rate by:
  • the step of determining the harmonic frequency comprises :
  • the determination of the pulse rate by the pulse rate estimator can include the steps of :
  • the quality metric is selected from the group comprising pulse signal shape, signal-to-noise ratio, correlation of the at least one wavelength of electromagnetic energy, arrhythmia probability, and, when there are two wavelengths of electromagnetic energy, a correlation between the data corresponding to the two wavelengths .
  • the pulse rate estimator in the second method aspect of the invention can determine its corresponding possible pulse rate by:
  • the method can include a step of identifying pulse data that is corrupted by motion, and rejecting that data.
  • the quality metric can then be selected from the group comprising a motion indication, and a proportion of motion corrupted pulse periods detected over a time interval .
  • the invention provides a method of determining a pulse rate of a patient using data corresponding to at least one wavelength of electromagnetic energy transmitted through tissue of the patient, which comprises:
  • the tracking step comprises:
  • the step of determining the harmonic frequency then comprises :
  • the tracking step can comprise:
  • the comparing step of the method comprises:
  • the arbitrating step of the method comprises:
  • the arbitrating step can comprise linearly interpolating between the first and second pulse rates to generate the patient's pulse rate where neither of the first and second confidence levels is greater than the other of the first and second confidence levels by more than a first amount.
  • the at least one quality metric corresponding to the first confidence level is selected from the group comprising pulse signal shape, signal-to-noise ratio, correlation of the at least one wavelength of electromagnetic energy, and arrhythmia probability.
  • the at least one quality metric corresponding to the first confidence level comprises a correlation between the data corresponding to the two wavelengths .
  • the at least one quality metric corresponding to the second confidence level is selected from the group comprising a motion indication, and a proportion of motion corrupted pulse periods detected over a time interval.
  • the method includes the steps of :
  • the invention can involve reduction of noise effects when measuring a physiological parameter. It can include apparatus for reducing the noise effects which comprises : means for generating a plurality of measurements derived from at least one wavelength of electromagnetic energy transmitted through living tissue; means for providing a signal indicative of the at least one wavelength of electromagnetic energy; means for comparing selected measurements with at least one expected measurement characteristic; means for assigning one of a plurality of variable weights to each selected measurement based on the comparing step thereby generating a plurality of differently weighted measurements for each wavelength, the variable weights being assigned, in part, in response to a similarity between each selected measurement and a corresponding previous measurement, the variable weights comprising a plurality of different nonzero numbers; means for averaging a plurality of the differently weighted measurements to obtain a filtered measurement for use in estimating the physiological parameter; and means for calibrating the system to measure the physiological parameter in response to the signal indicative of the at least one wavelength of electromagnetic energy.
  • the invention also includes a monitor for measuring a physiological parameter, the monitor being for use with a sensor having emitting means for emitting at least one wavelength of electromagnetic energy, sensing means for sensing the electromagnetic energy and for generating a first signal representative thereof, means for detachably coupling the sensor to the oximeter and for providing communication of signals between the sensor and the oximeter, and means for providing a second signal indicative of the at least one wavelength of electromagnetic energy, the monitor comprising: means for generating a plurality of measurements derived from the first signal; means for comparing selected measurements with at least one expected measurement characteristic; means for assigning one of a plurality of variable weights to each selected measurement based on the comparing step thereby generating a plurality of differently weighted measurements, the variable weights being assigned, in part, in response to a similarity between each selected measurement and a corresponding previous measurement, the variable weights comprising a plurality of different non-zero numbers; means for averaging a plurality of the differently weighted measurements to obtain a filtered measurement for
  • the present invention can be applied to blood oxygen saturation values calculated using Kalman filtering techniques (with or without cardiac gated averaging) as disclosed in the International patent application no. IB96/ (P21977A) referred to above.
  • Metrics that can be calculated from these algorithms include :
  • the present invention can be applied to pulse rate values calculated using a comb filter as disclosed in the International patent application no. [] referred to above.
  • Metrics that can be calculated from these algorithms include :
  • Validity a heuristic metric based on the strength of harmonics in the pulse, i.e., the shape of the pulse;
  • Arrhythmia probability a function of S/N vs.
  • Motion flag set when motion is detected
  • Motion Percent percentage of motion corrupted patterns detected in the last ten seconds .
  • the confidence interval for a pulse rate measured using an adaptive comb filter is a function of the validity metric and the arrhythmia probability metric. This space divides into several regions in which one or both metrics are the determining factor in how likely the adaptive comb filter is to be tracking the correct rate.
  • the Age and Deviation metrics can be used to determine saturation.
  • Filtered (n+1) (1 + W) * Filtered (n) - W * Raw, where the age of Filtered and Raw are known, and Filtered (n) is the value at sample number n, is described by the following steps :
  • the technique of the invention involves evaluation of several properties of the incoming oximetry signal, independent of the confidence metrics for the parameter in question (for example oxygen saturation and pulse rate) to determine whether the signal is actually due to a human pulse and what should appear on the display that is provided.
  • Possible states include:
  • Pulse lost when the pulse disappears and the sensor is still on the patient
  • Non-pulse when the oximetry signal comes from a signal other than a human pulse because the sensor has fallen off or is seeing an enormous amount of interference;
  • the possible actions in response to the occurrence of these various states are to update the display, hold the current values, or clear the display, for example blanks, dashes, zeroes, etc.
  • Pulse lost The criteria for the various states are evaluated in the following order: Pulse lost: The % IR modulation is below a threshold for period of seconds, or the criteria for Non-pulse are met and the previous state had been Pulse lost .
  • Non-pulse The uncorrelation is high and the percentage of energy above 5 Hz is high, OR the percent IR modulation is low. This criterion has been true for ten seconds continuously. If this criterion has been true for less than ten seconds, the Not Sure state is declared.
  • Pulse present The state is not one of the above states.
  • the criteria for the various display actions are UPDATE when the state is Pulse present, HOLD when the state is Not Sure or No contact, and CLEAR when the state is Disconnect, Pulse lost, or Non-pulse.
  • the best saturation is displayed when 1) the signal state action is UPDATE, and 2) the best saturation is sufficiently recent. Saturation is held when 1) the conditions for displaying the best saturation are not met, 2) the displayed saturation is less than sufficiently recent, and 3) the signal state action is not CLEAR. Saturation is blanked when 1) the conditions for displaying the best saturation are not met, and 2) the conditions for holding the saturation are not met.
  • the best heart rate is displayed when 1) the best calculated heart rate has a high confidence, and 2) the signal state action is UPDATE.
  • the heart rate is held when 1) the conditions for displaying the current heart rate are not met, 2) the displayed heart rate is sufficiently recent, and 3) the signal state action is not CLEAR.
  • the heart rate is blanked when 1) the conditions for displaying the current heart rate are not met, and 2) the conditions for holding the heart rate are not met .

Abstract

A method of measuring a blood constituent value using data comprising a single data set comprises: (a) determining a plurality of possible blood constituent values using a plurality of blood constituent value calculators, each of the blood constituent value calculators using the single data set, each of the possible blood constituent values having a confidence level associated therewith based on at least one quality metric; and (b) arbitrating between the plurality of possible blood constituent values with regard to the confidence levels to determine a measure of the blood constituent.

Description

METHOD AND APPARATUS FOR ARBITRATING TO OBTAIN BEST ESTIMATES FOR BLOOD CONSTITUENT VALUES & REJECTING HARMONICS
This invention relates to a method and apparatus for measuring physiological parameters, in particular for processing data so that its reliability can be assessed. It relates in particular to a method and apparatus for arbitrating to obtain best estimates for blood constituent values and rejecting harmonics.
Pulse oximeters typically measure and display various blood flow characteristics including the oxygen saturation of haemoglobin in arterial blood and pulse rate. Oximeters pass light through blood perfused tissue such as a finger or an ear, and photoelectrically sense the absorption of light in the tissue. The amount of light absorbed is then used to calculate the amount of the blood constituent (for example oxyhaemo- globin) being measured.
Techniques for calculating blood oxygen saturation levels in haemoglobin are disclosed in International patent application no. IB96/ filed with the present application entitled METHOD AND APPARATUS FOR ADAPTIVELY AVERAGING DATA SIGNALS, which bears the reference P21977A. Information concerning these features of the present invention that is disclosed in those documents is incorporated in the specification of the present application by this reference. The disclosed technique involves assigning varying weights to different measurements, the weighted measurements being averaged to obtain a filtered measurement. It employs Kalman filtering techniques to calculate blood oxygen saturation. Kalman filtering allows one to fit parameters in a least squares sense when the parameters are varying in time.
Other techniques for calculating blood oxygen saturation levels in haemoglobin, in which a harmonic filter is used to reduce noise effects, are disclosed in International patent application no. IB96/ filed with the present application entitled METHOD AND APPARATUS FOR HARMONICALLY FILTERING DATA, entitled METHOD AND APPARATUS FOR HARMONICALLY FILTERING DATA, which bears the reference P21977D. Information concerning these features of the present invention that is disclosed in that document is incorporated in the specification of the present application by this reference.
Techniques for determining pulse rates are disclosed in International patent application no. IB96/ filed with the present application entitled METHOD AND APPARATUS FOR MEASURING PULSE RATE AND SATURATION, which bears the reference P21977B. Information concerning these features of the present invention that is disclosed in this document is incorporated in the specification of the present application by this reference. A technique disclosed in the document involves use of a comb filter to isolate signal energy which corresponds to fundamental and related frequencies.
The present invention provides a technique for assessing signals relating to physiological parameters, in particular blood oxygen saturation and pulse rate, to determine whether and how they are to be displayed. The signals can be derived using techniques of the type that are disclosed in the specifications of the three applications referred to above. The technique of the invention involves arbitrating between possible values of the parameter in question according to a confidence level associated with each value based in a quality metric .
Accordingly, in one aspect, the invention provides a method of measuring a blood constituent value (for example, oxygenated haemoglobin in blood) using data comprising a single data set, which comprises :
(a) determining a plurality of possible blood constituent values using a plurality of blood constituent value calculators, each of the blood constituent value calculators using the single data set, each of the possible blood constituent values having a confidence level associated therewith based on at least one quality metric; and
(b) arbitrating between the plurality of possible blood constituent values with regard to the confidence levels to determine a measure of the blood constituent.
In another aspect, the invention provides apparatus for measuring a blood constituent using a single data set, by applying the method referred to above.
In a further aspect, the invention provides a method of determining a patient's pulse rate using data comprising a single data set corresponding to electromagnetic energy transmitted through the tissue of a patient, the method comprising the steps of :
(a) determining a plurality of possible pulse rates using a plurality of pulse rate estimators, each of the pulse rate estimators using the single data set, each of the possible pulse rates having a confidence level associated therewith based on at least one quality metric; and
(b) arbitrating between the plurality of possible pulse rates with regard to the confidence levels to determine the patient's pulse rate.
In yet another aspect, the invention provides apparatus for determining a patient's pulse rate using a single data set, by applying the method referred to above .
Preferably, the arbitrating step comprises:
(a) comparing the confidence levels for each of the values with the confidence levels for other values; and (b) selecting as the measure of the blood constituent or of the pulse rate (as the case may be) one of the plurality of possible values having a confidence level greater than all other confidence levels by at least a first amount.
Preferably, the arbitrating step comprises linearly interpolating between the plurality of possible values to generate the measure of the blood constituent or the patient's pulse rate (as the case may be) where none of the confidence levels is greater than all other confidence levels by more than a first amount .
When the method is measuring a blood constituent value, it is preferred that the quality metric is selected from the group comprising age of the possible blood constituent value and variance of the possible blood constituent value.
Preferably, in the second method aspect of the invention, the pulse rate estimator determines its corresponding possible pulse rate by:
(a) defining a comb filter to remove signal energy from the data corresponding to a fundamental frequency and harmonics thereof;
(b) determining a particular harmonic frequency which minimizes noise energy at an output of the comb filter, the particular harmonic frequency corresponding to the fundamental frequency; and
(c) generating the possible pulse rate corresponding to the particular harmonic frequency.
Preferably, the step of determining the harmonic frequency comprises :
(a) calculating squared noise for the data; (b) calculating a second derivative of the squared noise with respect to the fundamental frequency; and
(c) performing a Newton-Raphson search to determine the particular harmonic frequency.
The determination of the pulse rate by the pulse rate estimator can include the steps of :
(a) evaluating a power spectrum corresponding to the data to determine which of a plurality of peaks in the power spectrum corresponds to the fundamental frequency; and
(b) verifying that the particular harmonic frequency corresponds to the fundamental frequency based on the evaluating step.
When the method is determining a patient's pulse rate, it is preferred that the quality metric is selected from the group comprising pulse signal shape, signal-to-noise ratio, correlation of the at least one wavelength of electromagnetic energy, arrhythmia probability, and, when there are two wavelengths of electromagnetic energy, a correlation between the data corresponding to the two wavelengths .
The pulse rate estimator in the second method aspect of the invention can determine its corresponding possible pulse rate by:
(a) comparing the data to a predetermined waveform template;
(b) identifying a sequence of waveform characteristics indicative of a waveform period;
(c) averaging a number of successive waveform periods to determine an average waveform period; and
(d) determining the corresponding possible pulse rate from the average waveform period. The method can include a step of identifying pulse data that is corrupted by motion, and rejecting that data.
The quality metric can then be selected from the group comprising a motion indication, and a proportion of motion corrupted pulse periods detected over a time interval .
In a yet further aspect, the invention provides a method of determining a pulse rate of a patient using data corresponding to at least one wavelength of electromagnetic energy transmitted through tissue of the patient, which comprises:
(a) tracking a fundamental frequency using an adaptive comb filter to filter the data and to thereby generate a first pulse rate, the first pulse rate having a first confidence level associated therewith based on at least one quality metric;
(b) comparing the data to a predetermined waveform template to generate a second pulse rate, the second pulse rate having a second confidence level associated therewith based on the at least one quality metric; and
(c) arbitrating between the first and second pulse rates with regard to the first and second confidence levels to determine the patient's pulse rate.
Preferably, the tracking step comprises:
(a) defining a comb filter to remove signal energy from the data corresponding to the fundamental frequency and harmonics thereof; and
(b) determining a particular harmonic frequency which minimizes noise energy at an output of the comb filter, the particular harmonic frequency corresponding to the fundamental frequency. Preferably, the step of determining the harmonic frequency then comprises :
(a) calculating squared noise for the data;
(b) calculating a second derivative of the squared noise with respect to the fundamental frequency; and
(c) performing a Newton-Raphson search to determine the fundamental frequency.
The tracking step can comprise:
(a) evaluating a power spectrum corresponding to the data to determine which of a plurality of peaks in the power spectrum corresponds to the fundamental frequency; and
(b) verifying that the particular harmonic frequency corresponds to the fundamental frequency based on the evaluating step.
It might also include a step of filtering the first pulse rate to determine a filtered first pulse rate, for example by a filtering technique such as Kalman filtering.
Preferably, the comparing step of the method comprises:
(a) identifying a sequence of waveform characteristics indicative of a waveform period;
(b) averaging a number of successive waveform periods to determine an average waveform period; and
(c) determining the second pulse rate from the average waveform period.
Preferably, the arbitrating step of the method comprises:
(a) comparing the first and second confidence levels; and (b) selecting as the patient's pulse rate one of the first and second confidence levels which is greater than the other of the first and second confidence levels by at least a first amount.
The arbitrating step can comprise linearly interpolating between the first and second pulse rates to generate the patient's pulse rate where neither of the first and second confidence levels is greater than the other of the first and second confidence levels by more than a first amount.
Preferably, the at least one quality metric corresponding to the first confidence level is selected from the group comprising pulse signal shape, signal-to-noise ratio, correlation of the at least one wavelength of electromagnetic energy, and arrhythmia probability.
Preferably, there are two wavelengths of electromagnetic energy, and the at least one quality metric corresponding to the first confidence level comprises a correlation between the data corresponding to the two wavelengths .
Preferably, the at least one quality metric corresponding to the second confidence level is selected from the group comprising a motion indication, and a proportion of motion corrupted pulse periods detected over a time interval.
Preferably, prior to the processing step, the method includes the steps of :
(a) taking the logarithm of a signal representative of the at least one wavelength of electromagnetic energy, thereby generating a first signal;
(b) band pass filtering the first signal, thereby generating a second signal; and
(c) normalizing the second signal, thereby generating the data; the tracking step comprising taking the derivative of the data.
The invention can involve reduction of noise effects when measuring a physiological parameter. It can include apparatus for reducing the noise effects which comprises : means for generating a plurality of measurements derived from at least one wavelength of electromagnetic energy transmitted through living tissue; means for providing a signal indicative of the at least one wavelength of electromagnetic energy; means for comparing selected measurements with at least one expected measurement characteristic; means for assigning one of a plurality of variable weights to each selected measurement based on the comparing step thereby generating a plurality of differently weighted measurements for each wavelength, the variable weights being assigned, in part, in response to a similarity between each selected measurement and a corresponding previous measurement, the variable weights comprising a plurality of different nonzero numbers; means for averaging a plurality of the differently weighted measurements to obtain a filtered measurement for use in estimating the physiological parameter; and means for calibrating the system to measure the physiological parameter in response to the signal indicative of the at least one wavelength of electromagnetic energy.
The invention also includes a monitor for measuring a physiological parameter, the monitor being for use with a sensor having emitting means for emitting at least one wavelength of electromagnetic energy, sensing means for sensing the electromagnetic energy and for generating a first signal representative thereof, means for detachably coupling the sensor to the oximeter and for providing communication of signals between the sensor and the oximeter, and means for providing a second signal indicative of the at least one wavelength of electromagnetic energy, the monitor comprising: means for generating a plurality of measurements derived from the first signal; means for comparing selected measurements with at least one expected measurement characteristic; means for assigning one of a plurality of variable weights to each selected measurement based on the comparing step thereby generating a plurality of differently weighted measurements, the variable weights being assigned, in part, in response to a similarity between each selected measurement and a corresponding previous measurement, the variable weights comprising a plurality of different non-zero numbers; means for averaging a plurality of the differently weighted measurements to obtain a filtered measurement for use in estimating the physiological parameter; and means for calibrating the monitor to measure the physiological parameter in response to the second signal .
There now follows a discussion of preferred methods of processing and displaying the blood oxygen saturation and pulse rate for use on a hospital floor. With metrics that are available from algorithms for measuring oxygen saturation levels and pulse rates, confidence levels for the saturation and the pulse rate values that are calculated can be estimated, thus determining which saturation and which pulse rate of the multiple pulse rates and multiple saturations can be considered reliable, and how long the saturation or pulse rate previously selected should be held when a current estimate is not considered sufficiently reliable.
The present invention can be applied to blood oxygen saturation values calculated using Kalman filtering techniques (with or without cardiac gated averaging) as disclosed in the International patent application no. IB96/ (P21977A) referred to above. Metrics that can be calculated from these algorithms include :
Age: effective averaging period is double this; and Deviation: standard deviation of saturation estimate in saturation points.
The present invention can be applied to pulse rate values calculated using a comb filter as disclosed in the International patent application no. [] referred to above. Metrics that can be calculated from these algorithms include :
Validity: a heuristic metric based on the strength of harmonics in the pulse, i.e., the shape of the pulse;
S/N: signal-to-noise ratio;
Arrhythmia probability: a function of S/N vs.
Uncorrelation averaged over time; and
Uncorrelation (IR _ red)
Figure imgf000013_0001
appropriate number of sample points.
Motion flag: set when motion is detected; and
Motion Percent: percentage of motion corrupted patterns detected in the last ten seconds .
The confidence interval for a pulse rate measured using an adaptive comb filter is a function of the validity metric and the arrhythmia probability metric. This space divides into several regions in which one or both metrics are the determining factor in how likely the adaptive comb filter is to be tracking the correct rate.
The Age and Deviation metrics can be used to determine saturation. A general algorithm for calculating the age of the output of an IIR filter having the form
Filtered (n+1) = (1 + W) * Filtered (n) - W * Raw, where the age of Filtered and Raw are known, and Filtered (n) is the value at sample number n, is described by the following steps :
1) Increment the age of Filtered by the amount of time elapsed since it was last calculated; and
2) Age of Filtered (n + 1) = (1 + W) * Age of Filtered (n) + W * Age of Raw
Preferably, the technique of the invention involves evaluation of several properties of the incoming oximetry signal, independent of the confidence metrics for the parameter in question (for example oxygen saturation and pulse rate) to determine whether the signal is actually due to a human pulse and what should appear on the display that is provided. Possible states include:
Disconnect : when the sensor is unplugged; No Contact : when the sensor does not make sufficient contact with the patient;
Pulse lost: when the pulse disappears and the sensor is still on the patient;
Non-pulse : when the oximetry signal comes from a signal other than a human pulse because the sensor has fallen off or is seeing an enormous amount of interference;
Pulse Present when the oximetry signal comes from a human pulse; and Not Sure : a waiting period before declaring a Disconnect or Non-pulse state.
The possible actions in response to the occurrence of these various states are to update the display, hold the current values, or clear the display, for example blanks, dashes, zeroes, etc.
The criteria for the various states are evaluated in the following order: Pulse lost: The % IR modulation is below a threshold for period of seconds, or the criteria for Non-pulse are met and the previous state had been Pulse lost .
Non-pulse: The uncorrelation is high and the percentage of energy above 5 Hz is high, OR the percent IR modulation is low. This criterion has been true for ten seconds continuously. If this criterion has been true for less than ten seconds, the Not Sure state is declared.
Pulse present: The state is not one of the above states.
The criteria for the various display actions are UPDATE when the state is Pulse present, HOLD when the state is Not Sure or No contact, and CLEAR when the state is Disconnect, Pulse lost, or Non-pulse.
The best saturation is displayed when 1) the signal state action is UPDATE, and 2) the best saturation is sufficiently recent. Saturation is held when 1) the conditions for displaying the best saturation are not met, 2) the displayed saturation is less than sufficiently recent, and 3) the signal state action is not CLEAR. Saturation is blanked when 1) the conditions for displaying the best saturation are not met, and 2) the conditions for holding the saturation are not met.
The best heart rate is displayed when 1) the best calculated heart rate has a high confidence, and 2) the signal state action is UPDATE. The heart rate is held when 1) the conditions for displaying the current heart rate are not met, 2) the displayed heart rate is sufficiently recent, and 3) the signal state action is not CLEAR. The heart rate is blanked when 1) the conditions for displaying the current heart rate are not met, and 2) the conditions for holding the heart rate are not met .

Claims

CLAIMS :
1. A method of measuring a blood constituent value using data comprising a single data set, which comprises:
(a) determining a plurality of possible blood constituent values using a plurality of blood constituent value calculators, each of the blood constituent value calculators using the single data set, each of the possible blood constituent values having a confidence level associated therewith based on at least one quality metric; and
(b) arbitrating between the plurality of possible blood constituent values with regard to the confidence levels to determine a measure of the blood constituent.
2. A method as claimed in claim 1, in which the arbitrating step comprises:
(a) comparing the confidence levels for each of the possible blood constituent values with the confidence levels for other blood constituent values; and
(b) selecting as the measure of the blood constituent one of the plurality of possible blood constituent values having a confidence level greater than all other confidence levels by at least a first amount.
3. A method as claimed in claim 1, in which the arbitrating step comprises linearly interpolating between the plurality of possible blood constituent values to generate the measure of the blood constituent where none of the confidence levels is greater than all other confidence levels by more than a first amount .
4. A method as claimed in claim 1, in which the at least one quality metric is selected from the group comprising age of the possible blood constituent value and variance of the possible blood constituent value.
5. A method as claimed in claim 1, in which the blood constituent comprises oxygenated haemoglobin in arterial blood.
6. Apparatus for measuring a blood constituent using a single data set, comprising:
(a) means for determining a plurality of possible blood constituent values using a plurality of blood constituent value calculators, each of the blood constituent value calculators using the single data set, each of the possible blood constituent values having a confidence level associated therewith based on at least one quality metric; and
(b) means for arbitrating between the plurality of possible blood constituent values with regard to the confidence levels to determine a measure of the blood constituent .
7. A method of determining a patient's pulse rate using data comprising a single data set corresponding to energy transmitted through the tissue of a patient, the method comprising the steps of :
(a) determining a plurality of possible pulse rates using a plurality of pulse rate estimators, each of the pulse rate estimators using the single data set, each of the possible pulse rates having a confidence level associated therewith based on at least one quality metric; and (b) arbitrating between the plurality of possible pulse rates with regard to the confidence levels to determine the patient's pulse rate.
8. A method as claimed in claim 7, in which the arbitrating step comprises :
(a) comparing the confidence levels for each of the possible pulse rates with the confidence levels for other possible pulse rates; and
(b) selecting as the patient's pulse rate one of the plurality of possible pulse rates having a confidence level greater than all other confidence levels by at least a first amount.
9. A method as claimed in claim 7, in which the arbitrating step comprises linearly interpolating between the plurality of possible pulse rates to generate the patient's pulse rate where none of the confidence levels is greater than all other confidence levels by more than a first amount.
10. A method as claimed in claim 7, in which one pulse rate estimator determines its corresponding possible pulse rate by:
(a) defining a comb filter to remove signal energy from the data corresponding to a fundamental frequency and harmonics thereof;
(b) determining a particular harmonic frequency which minimizes noise energy at an output of the comb filter, the particular harmonic frequency corresponding to the fundamental frequency; and
(c) generating the possible pulse rate corresponding to the particular harmonic frequency.
11. A method as claimed in claim 10, in which the determining step comprises :
(a) calculating squared noise for the data;
(b) calculating a second derivative of the squared noise with respect to the fundamental frequency; and
(c) performing a Newton-Raphson search to determine the particular harmonic frequency.
12. A method as claimed in claim 10 further comprising the steps of :
(a) evaluating a power spectrum corresponding to the data to determine which of a plurality of peaks in the power spectrum corresponds to the fundamental frequency; and
(b) verifying that the particular harmonic frequency corresponds to the fundamental frequency based on the evaluating step.
13. A method as claimed in claim 10, in which the at least one quality metric is selected from the group comprising pulse signal shape, signal-to-noise ratio, correlation of the at least one wavelength of electromagnetic energy, and arrhythmia probability.
14. A method as claimed in claim 10, in which there are two wavelengths of electromagnetic energy, and the at least one quality metric comprises a correlation between the data corresponding to the two wavelengths .
15. A method as claimed in claim 7, in which one pulse rate estimator determines its corresponding possible pulse rate by: (a) comparing the data to a predetermined waveform template;
(b) identifying a sequence of waveform characteristics indicative of a waveform period;
(c) averaging a number of successive waveform periods to determine an average waveform period; and
(d) determining the corresponding possible pulse rate from the average waveform period.
16. A method as claimed in claim 15, in which the at least one quality metric is selected from the group comprising a motion indication, and a proportion of motion corrupted pulse periods detected over a time interval.
17. A method of determining a pulse rate of a patient using data corresponding to at least one wavelength of electromagnetic energy transmitted through tissue of the patient, which comprises:
(a) tracking a fundamental frequency using an adaptive comb filter to filter the data and to thereby generate a first pulse rate, the first pulse rate having a first confidence level associated therewith based on at least one quality metric;
(b) comparing the data to a predetermined waveform template to generate a second pulse rate, the second pulse rate having a second confidence level associated therewith based on the at least one quality metric; and
(c) arbitrating between the first and second pulse rates with regard to the first and second confidence levels to determine the patient's pulse rate.
18. A method as claimed in claim 17, in which the tracking step comprises:
(a) defining a comb filter to remove signal energy from the data corresponding to the fundamental frequency and harmonics thereof; and
(b) determining a particular harmonic frequency which minimizes noise energy at an output of the comb filter, the particular harmonic frequency corresponding to the fundamental frequency.
19. A method as claimed in claim 18, in which the determining step comprises:
(a) calculating squared noise for the data;
(b) calculating a second derivative of the squared noise with respect to the fundamental frequency; and
(c) performing a Newton-Raphson search to determine the fundamental frequency.
20. A method as claimed in claim 18, in which the tracking step comprises :
(a) evaluating a power spectrum corresponding to the data to determine which of a plurality of peaks in the power spectrum corresponds to the fundamental frequency; and
(b) verifying that the particular harmonic frequency corresponds to the fundamental frequency based on the evaluating step.
21. A method as claimed in claim 17, in which the tracking step comprises Kalman filtering the first pulse rate to determine a filtered first pulse rate.
22. A method as claimed in claim 17, in which the comparing step comprises:
(a) identifying a sequence of waveform characteristics indicative of a waveform period;
(b) averaging a number of successive waveform periods to determine an average waveform period; and
(c) determining the second pulse rate from the average waveform period.
23. A method as claimed in claim 17, in which the arbitrating step comprises:
(a) comparing the first and second confidence levels; and
(b) selecting as the patient's pulse rate one of the first and second confidence levels which is greater than the other of the first and second confidence levels by at least a first amount.
24. A method as claimed in claim 17, in which the arbitrating step comprises linearly interpolating between the first and second pulse rates to generate the patient's pulse rate where neither of the first and second confidence levels is greater than the other of the first and second confidence levels by more than a first amount.
25. A method as claimed in claim 17, in which the at least one quality metric corresponding to the first confidence level is selected from the group comprising pulse signal shape, signal-to-noise ratio, correlation of the at least one wavelength of electromagnetic energy, and arrhythmia probability. ~
26. A method as claimed in claim 17, in which there are two wavelengths of electromagnetic energy, and the at least one quality metric corresponding to the first confidence level comprises a correlation between the data corresponding to the two wavelengths .
27. A method as claimed in claim 17, in which the at least one quality metric corresponding to the second confidence level is selected from the group comprising a motion indication, and a proportion of motion corrupted pulse periods detected over a time interval.
28. A method as claimed in claim 17, which includes, before the processing step, the steps of:
(a) taking the logarithm of a signal representative of the at least one wavelength of electromagnetic energy, thereby generating a first signal;
(b) band pass filtering the first signal, thereby generating a second signal; and
(c) normalizing the second signal, thereby generating the data;
and in which the tracking step comprises taking the derivative of the data.
PCT/IB1997/000292 1997-03-21 1997-03-21 Method and apparatus for arbitrating to obtain best estimates for blood constituent values and rejecting harmonics WO1998043071A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP97906323A EP0966665A1 (en) 1997-03-21 1997-03-21 Method and apparatus for arbitrating to obtain best estimates for blood constituent values and rejecting harmonics
CA002283860A CA2283860A1 (en) 1997-03-21 1997-03-21 Method and apparatus for arbitrating to obtain best estimates for blood constituent values and rejecting harmonics
AU21052/97A AU736060B2 (en) 1997-03-21 1997-03-21 Method and apparatus for arbitrating to obtain best estimates for blood constituent values and rejecting harmonics
PCT/IB1997/000292 WO1998043071A1 (en) 1997-03-21 1997-03-21 Method and apparatus for arbitrating to obtain best estimates for blood constituent values and rejecting harmonics
JP54325698A JP2001517128A (en) 1997-03-21 1997-03-21 Method and apparatus for arbitrating and removing harmonics to obtain the best evaluation of blood component values

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1997/000292 WO1998043071A1 (en) 1997-03-21 1997-03-21 Method and apparatus for arbitrating to obtain best estimates for blood constituent values and rejecting harmonics

Publications (1)

Publication Number Publication Date
WO1998043071A1 true WO1998043071A1 (en) 1998-10-01

Family

ID=11004543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1997/000292 WO1998043071A1 (en) 1997-03-21 1997-03-21 Method and apparatus for arbitrating to obtain best estimates for blood constituent values and rejecting harmonics

Country Status (5)

Country Link
EP (1) EP0966665A1 (en)
JP (1) JP2001517128A (en)
AU (1) AU736060B2 (en)
CA (1) CA2283860A1 (en)
WO (1) WO1998043071A1 (en)

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002091918A3 (en) * 2001-05-15 2003-05-01 Masimo Corp Pulse oximetry data confidence indicator
US6606511B1 (en) 1999-01-07 2003-08-12 Masimo Corporation Pulse oximetry pulse indicator
WO2006094107A1 (en) * 2005-03-01 2006-09-08 Masimo Laboratories, Inc. Physiological parameter confidence measure
US7376453B1 (en) 1993-10-06 2008-05-20 Masimo Corporation Signal processing apparatus
US7668579B2 (en) 2006-02-10 2010-02-23 Lynn Lawrence A System and method for the detection of physiologic response to stimulation
US7684842B2 (en) 2006-09-29 2010-03-23 Nellcor Puritan Bennett Llc System and method for preventing sensor misuse
US7890154B2 (en) 2004-03-08 2011-02-15 Nellcor Puritan Bennett Llc Selection of ensemble averaging weights for a pulse oximeter based on signal quality metrics
US8211708B2 (en) 2009-03-13 2012-07-03 Furukawa Electric Co., Ltd. Optical measuring device and method therefor
US8219170B2 (en) 2006-09-20 2012-07-10 Nellcor Puritan Bennett Llc System and method for practicing spectrophotometry using light emitting nanostructure devices
US8265724B2 (en) 2007-03-09 2012-09-11 Nellcor Puritan Bennett Llc Cancellation of light shunting
US8280469B2 (en) 2007-03-09 2012-10-02 Nellcor Puritan Bennett Llc Method for detection of aberrant tissue spectra
US8315685B2 (en) 2006-09-27 2012-11-20 Nellcor Puritan Bennett Llc Flexible medical sensor enclosure
US8401606B2 (en) 2001-07-19 2013-03-19 Covidien Lp Nuisance alarm reductions in a physiological monitor
US8521246B2 (en) 2010-07-29 2013-08-27 Covidien Lp Cable cross talk suppression
US8666467B2 (en) 2001-05-17 2014-03-04 Lawrence A. Lynn System and method for SPO2 instability detection and quantification
US8761854B2 (en) 2010-04-30 2014-06-24 Coviden Lp Method for respiration rate and blood pressure alarm management
US8862196B2 (en) 2001-05-17 2014-10-14 Lawrence A. Lynn System and method for automatic detection of a plurality of SP02 time series pattern types
US8874181B2 (en) 2004-02-25 2014-10-28 Covidien Lp Oximeter ambient light cancellation
US8888708B2 (en) 1997-04-14 2014-11-18 Masimo Corporation Signal processing apparatus and method
US8922788B2 (en) 2012-12-22 2014-12-30 Covidien Lp Methods and systems for determining a probe-off condition in a medical device
US8930145B2 (en) 2010-07-28 2015-01-06 Covidien Lp Light focusing continuous wave photoacoustic spectroscopy and its applications to patient monitoring
US8942777B2 (en) 1991-03-07 2015-01-27 Masimo Corporation Signal processing apparatus
US8965471B2 (en) 2007-04-21 2015-02-24 Cercacor Laboratories, Inc. Tissue profile wellness monitor
US8965473B2 (en) 2005-09-29 2015-02-24 Covidien Lp Medical sensor for reducing motion artifacts and technique for using the same
US8968193B2 (en) 2008-09-30 2015-03-03 Covidien Lp System and method for enabling a research mode on physiological monitors
US8983800B2 (en) 2003-01-13 2015-03-17 Covidien Lp Selection of preset filter parameters based on signal quality
US9031793B2 (en) 2001-05-17 2015-05-12 Lawrence A. Lynn Centralized hospital monitoring system for automatically detecting upper airway instability and for preventing and aborting adverse drug reactions
US9042952B2 (en) 1997-01-27 2015-05-26 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US9053222B2 (en) 2002-05-17 2015-06-09 Lawrence A. Lynn Patient safety processor
USD736250S1 (en) 2008-06-30 2015-08-11 Covidien Lp Portion of a display panel with an indicator icon
US9131883B2 (en) 2002-01-24 2015-09-15 Masimo Corporation Physiological trend monitor
US9138192B2 (en) 2000-06-05 2015-09-22 Masimo Corporation Variable indication estimator
US9161713B2 (en) 2004-03-04 2015-10-20 Masimo Corporation Multi-mode patient monitor configured to self-configure for a selected or determined mode of operation
US9204844B2 (en) 2005-09-29 2015-12-08 Covidien Lp System and method for removing artifacts from waveforms
US9351674B2 (en) 2005-03-03 2016-05-31 Covidien Lp Method for enhancing pulse oximetry calculations in the presence of correlated artifacts
US9380969B2 (en) 2009-07-30 2016-07-05 Covidien Lp Systems and methods for varying a sampling rate of a signal
US9468378B2 (en) 1997-01-27 2016-10-18 Lawrence A. Lynn Airway instability detection system and method
WO2016178119A1 (en) * 2015-04-27 2016-11-10 LifeWatch Technologies, Ltd. Positioning a medical device based on oxygen saturation measurements
US9521971B2 (en) 1997-07-14 2016-12-20 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US9560995B2 (en) 2013-02-25 2017-02-07 Covidien Lp Methods and systems for determining a probe-off condition in a medical device
US9622693B2 (en) 2002-12-04 2017-04-18 Masimo Corporation Systems and methods for determining blood oxygen saturation values using complex number encoding
US9675286B2 (en) 1998-12-30 2017-06-13 Masimo Corporation Plethysmograph pulse recognition processor
US9833146B2 (en) 2012-04-17 2017-12-05 Covidien Lp Surgical system and method of use of the same
US9839381B1 (en) 2009-11-24 2017-12-12 Cercacor Laboratories, Inc. Physiological measurement system with automatic wavelength adjustment
US9895068B2 (en) 2008-06-30 2018-02-20 Covidien Lp Pulse oximeter with wait-time indication
US10076276B2 (en) 2008-02-19 2018-09-18 Covidien Lp Methods and systems for alerting practitioners to physiological conditions
US10092193B2 (en) 2012-02-24 2018-10-09 Covidien Lp Hypovolemia diagnosis technique
US10194870B2 (en) 2015-05-27 2019-02-05 Covidien Lp Systems and methods for optimizing autoregulation measurements
US10219705B2 (en) 2015-05-08 2019-03-05 Covidien Lp System and method for identifying autoregulation zones
US10226188B2 (en) 2013-08-23 2019-03-12 Covidien Lp Systems and methods for monitoring blood pressure
US10271779B2 (en) 2015-06-30 2019-04-30 Covidien Lp System and method of monitoring autoregulation
US10292663B2 (en) 2015-06-30 2019-05-21 Covidien Lp System and method of monitoring autoregulation
US10354753B2 (en) 2001-05-17 2019-07-16 Lawrence A. Lynn Medical failure pattern search engine
US10383579B2 (en) 2014-10-16 2019-08-20 Covidien Lp System and method for monitoring autoregulation
US10463292B2 (en) 2015-10-16 2019-11-05 Covidien Lp System and method for identifying autoregulation zones
US10478107B2 (en) 2009-07-29 2019-11-19 Masimo Corporation Non-invasive physiological sensor cover
US10499818B2 (en) 2015-10-19 2019-12-10 Covidien Lp System and method for providing blood pressure safe zone indication during autoregulation monitoring
US10729402B2 (en) 2009-12-04 2020-08-04 Masimo Corporation Calibration for multi-stage physiological monitors
US10736578B2 (en) 2016-07-14 2020-08-11 Covidien Lp Systems and methods of monitoring autoregulation
US10932724B2 (en) 2015-06-17 2021-03-02 Covidien Lp Systems and methods for monitoring autoregulation using a confidence level
US10959652B2 (en) 2001-07-02 2021-03-30 Masimo Corporation Low power pulse oximeter
US11096588B2 (en) 2015-10-06 2021-08-24 Covidien Lp System and method for monitoring autoregulation utilizing normalized regional oxygen saturation values
US11419506B2 (en) 2016-08-22 2022-08-23 Covidien Lp System and method for identifying blood pressure zones during autoregulation monitoring
US11759130B2 (en) 2006-10-12 2023-09-19 Masimo Corporation Perfusion index smoother

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5260949B2 (en) * 2007-04-27 2013-08-14 古河電気工業株式会社 Optical measuring device and optical measuring method

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522674A2 (en) * 1991-07-12 1993-01-13 Mark R. Robinson Oximeter for reliable clinical determination of blood oxygen saturation in a fetus
US5355880A (en) * 1992-07-06 1994-10-18 Sandia Corporation Reliable noninvasive measurement of blood gases
DE4339067A1 (en) * 1993-11-16 1995-05-18 Jenoptik Jena Gmbh Method and arrangement for the non-invasive, transcutaneous determination of substance concentrations in body fluid or human tissue
US5435309A (en) * 1993-08-10 1995-07-25 Thomas; Edward V. Systematic wavelength selection for improved multivariate spectral analysis
WO1995034806A1 (en) * 1994-06-10 1995-12-21 Tim Liesenhoff Reflection spectroscopic device
WO1996030742A1 (en) * 1995-03-30 1996-10-03 Chiron Diagnostics Corporation Method for oximeter standardization and for reporting results

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522674A2 (en) * 1991-07-12 1993-01-13 Mark R. Robinson Oximeter for reliable clinical determination of blood oxygen saturation in a fetus
US5355880A (en) * 1992-07-06 1994-10-18 Sandia Corporation Reliable noninvasive measurement of blood gases
US5435309A (en) * 1993-08-10 1995-07-25 Thomas; Edward V. Systematic wavelength selection for improved multivariate spectral analysis
DE4339067A1 (en) * 1993-11-16 1995-05-18 Jenoptik Jena Gmbh Method and arrangement for the non-invasive, transcutaneous determination of substance concentrations in body fluid or human tissue
WO1995034806A1 (en) * 1994-06-10 1995-12-21 Tim Liesenhoff Reflection spectroscopic device
WO1996030742A1 (en) * 1995-03-30 1996-10-03 Chiron Diagnostics Corporation Method for oximeter standardization and for reporting results

Cited By (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8942777B2 (en) 1991-03-07 2015-01-27 Masimo Corporation Signal processing apparatus
US8948834B2 (en) 1991-03-07 2015-02-03 Masimo Corporation Signal processing apparatus
US7376453B1 (en) 1993-10-06 2008-05-20 Masimo Corporation Signal processing apparatus
US9468378B2 (en) 1997-01-27 2016-10-18 Lawrence A. Lynn Airway instability detection system and method
US9042952B2 (en) 1997-01-27 2015-05-26 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US9289167B2 (en) 1997-04-14 2016-03-22 Masimo Corporation Signal processing apparatus and method
US8888708B2 (en) 1997-04-14 2014-11-18 Masimo Corporation Signal processing apparatus and method
US9521971B2 (en) 1997-07-14 2016-12-20 Lawrence A. Lynn System and method for automatic detection of a plurality of SPO2 time series pattern types
US9675286B2 (en) 1998-12-30 2017-06-13 Masimo Corporation Plethysmograph pulse recognition processor
US10130289B2 (en) 1999-01-07 2018-11-20 Masimo Corporation Pulse and confidence indicator displayed proximate plethysmograph
US6606511B1 (en) 1999-01-07 2003-08-12 Masimo Corporation Pulse oximetry pulse indicator
US6684090B2 (en) 1999-01-07 2004-01-27 Masimo Corporation Pulse oximetry data confidence indicator
US10357206B2 (en) 2000-06-05 2019-07-23 Masimo Corporation Variable indication estimator
US9138192B2 (en) 2000-06-05 2015-09-22 Masimo Corporation Variable indication estimator
US8932227B2 (en) 2000-07-28 2015-01-13 Lawrence A. Lynn System and method for CO2 and oximetry integration
US10058269B2 (en) 2000-07-28 2018-08-28 Lawrence A. Lynn Monitoring system for identifying an end-exhalation carbon dioxide value of enhanced clinical utility
WO2002091918A3 (en) * 2001-05-15 2003-05-01 Masimo Corp Pulse oximetry data confidence indicator
US8666467B2 (en) 2001-05-17 2014-03-04 Lawrence A. Lynn System and method for SPO2 instability detection and quantification
US10032526B2 (en) 2001-05-17 2018-07-24 Lawrence A. Lynn Patient safety processor
US10354753B2 (en) 2001-05-17 2019-07-16 Lawrence A. Lynn Medical failure pattern search engine
US10366790B2 (en) 2001-05-17 2019-07-30 Lawrence A. Lynn Patient safety processor
US11439321B2 (en) 2001-05-17 2022-09-13 Lawrence A. Lynn Monitoring system for identifying an end-exhalation carbon dioxide value of enhanced clinical utility
US8862196B2 (en) 2001-05-17 2014-10-14 Lawrence A. Lynn System and method for automatic detection of a plurality of SP02 time series pattern types
US9031793B2 (en) 2001-05-17 2015-05-12 Lawrence A. Lynn Centralized hospital monitoring system for automatically detecting upper airway instability and for preventing and aborting adverse drug reactions
US10297348B2 (en) 2001-05-17 2019-05-21 Lawrence A. Lynn Patient safety processor
US10959652B2 (en) 2001-07-02 2021-03-30 Masimo Corporation Low power pulse oximeter
US10980455B2 (en) 2001-07-02 2021-04-20 Masimo Corporation Low power pulse oximeter
US11219391B2 (en) 2001-07-02 2022-01-11 Masimo Corporation Low power pulse oximeter
US8838196B2 (en) 2001-07-19 2014-09-16 Covidien Lp Nuisance alarm reductions in a physiological monitor
US8401607B2 (en) 2001-07-19 2013-03-19 Covidien Lp Nuisance alarm reductions in a physiological monitor
US8401606B2 (en) 2001-07-19 2013-03-19 Covidien Lp Nuisance alarm reductions in a physiological monitor
US9636056B2 (en) 2002-01-24 2017-05-02 Masimo Corporation Physiological trend monitor
USRE49034E1 (en) 2002-01-24 2022-04-19 Masimo Corporation Physiological trend monitor
US9131883B2 (en) 2002-01-24 2015-09-15 Masimo Corporation Physiological trend monitor
US9053222B2 (en) 2002-05-17 2015-06-09 Lawrence A. Lynn Patient safety processor
US9622693B2 (en) 2002-12-04 2017-04-18 Masimo Corporation Systems and methods for determining blood oxygen saturation values using complex number encoding
US8983800B2 (en) 2003-01-13 2015-03-17 Covidien Lp Selection of preset filter parameters based on signal quality
US8874181B2 (en) 2004-02-25 2014-10-28 Covidien Lp Oximeter ambient light cancellation
US9161713B2 (en) 2004-03-04 2015-10-20 Masimo Corporation Multi-mode patient monitor configured to self-configure for a selected or determined mode of operation
EP2260758B1 (en) * 2004-03-08 2020-08-19 Covidien LP Selection of ensemble averaging weights for a pulse oximeter based on signal quality metrics
US7890154B2 (en) 2004-03-08 2011-02-15 Nellcor Puritan Bennett Llc Selection of ensemble averaging weights for a pulse oximeter based on signal quality metrics
US9351675B2 (en) 2005-03-01 2016-05-31 Cercacor Laboratories, Inc. Noninvasive multi-parameter patient monitor
US9750443B2 (en) 2005-03-01 2017-09-05 Cercacor Laboratories, Inc. Multiple wavelength sensor emitters
US11430572B2 (en) 2005-03-01 2022-08-30 Cercacor Laboratories, Inc. Multiple wavelength sensor emitters
US9167995B2 (en) 2005-03-01 2015-10-27 Cercacor Laboratories, Inc. Physiological parameter confidence measure
US10123726B2 (en) 2005-03-01 2018-11-13 Cercacor Laboratories, Inc. Configurable physiological measurement system
US9241662B2 (en) 2005-03-01 2016-01-26 Cercacor Laboratories, Inc. Configurable physiological measurement system
US8912909B2 (en) 2005-03-01 2014-12-16 Cercacor Laboratories, Inc. Noninvasive multi-parameter patient monitor
US10251585B2 (en) 2005-03-01 2019-04-09 Cercacor Laboratories, Inc. Noninvasive multi-parameter patient monitor
US10327683B2 (en) 2005-03-01 2019-06-25 Cercacor Laboratories, Inc. Multiple wavelength sensor emitters
EP2286721A3 (en) * 2005-03-01 2012-07-04 Masimo Laboratories, Inc. Physiological Parameter Confidence Measure
US10984911B2 (en) 2005-03-01 2021-04-20 Cercacor Laboratories, Inc. Multiple wavelength sensor emitters
WO2006094107A1 (en) * 2005-03-01 2006-09-08 Masimo Laboratories, Inc. Physiological parameter confidence measure
US8929964B2 (en) 2005-03-01 2015-01-06 Cercacor Laboratories, Inc. Multiple wavelength sensor drivers
US8849365B2 (en) 2005-03-01 2014-09-30 Cercacor Laboratories, Inc. Multiple wavelength sensor emitters
US9549696B2 (en) 2005-03-01 2017-01-24 Cercacor Laboratories, Inc. Physiological parameter confidence measure
US10856788B2 (en) 2005-03-01 2020-12-08 Cercacor Laboratories, Inc. Noninvasive multi-parameter patient monitor
US11545263B2 (en) 2005-03-01 2023-01-03 Cercacor Laboratories, Inc. Multiple wavelength sensor emitters
US9131882B2 (en) 2005-03-01 2015-09-15 Cercacor Laboratories, Inc. Noninvasive multi-parameter patient monitor
US9351674B2 (en) 2005-03-03 2016-05-31 Covidien Lp Method for enhancing pulse oximetry calculations in the presence of correlated artifacts
US8965473B2 (en) 2005-09-29 2015-02-24 Covidien Lp Medical sensor for reducing motion artifacts and technique for using the same
US9204844B2 (en) 2005-09-29 2015-12-08 Covidien Lp System and method for removing artifacts from waveforms
US8728001B2 (en) 2006-02-10 2014-05-20 Lawrence A. Lynn Nasal capnographic pressure monitoring system
US7668579B2 (en) 2006-02-10 2010-02-23 Lynn Lawrence A System and method for the detection of physiologic response to stimulation
US8219170B2 (en) 2006-09-20 2012-07-10 Nellcor Puritan Bennett Llc System and method for practicing spectrophotometry using light emitting nanostructure devices
US8315685B2 (en) 2006-09-27 2012-11-20 Nellcor Puritan Bennett Llc Flexible medical sensor enclosure
US7684842B2 (en) 2006-09-29 2010-03-23 Nellcor Puritan Bennett Llc System and method for preventing sensor misuse
US11759130B2 (en) 2006-10-12 2023-09-19 Masimo Corporation Perfusion index smoother
US8280469B2 (en) 2007-03-09 2012-10-02 Nellcor Puritan Bennett Llc Method for detection of aberrant tissue spectra
US8265724B2 (en) 2007-03-09 2012-09-11 Nellcor Puritan Bennett Llc Cancellation of light shunting
US10251586B2 (en) 2007-04-21 2019-04-09 Masimo Corporation Tissue profile wellness monitor
US11647923B2 (en) 2007-04-21 2023-05-16 Masimo Corporation Tissue profile wellness monitor
US8965471B2 (en) 2007-04-21 2015-02-24 Cercacor Laboratories, Inc. Tissue profile wellness monitor
US9848807B2 (en) 2007-04-21 2017-12-26 Masimo Corporation Tissue profile wellness monitor
US10980457B2 (en) 2007-04-21 2021-04-20 Masimo Corporation Tissue profile wellness monitor
US10076276B2 (en) 2008-02-19 2018-09-18 Covidien Lp Methods and systems for alerting practitioners to physiological conditions
US11298076B2 (en) 2008-02-19 2022-04-12 Covidien Lp Methods and systems for alerting practitioners to physiological conditions
US9895068B2 (en) 2008-06-30 2018-02-20 Covidien Lp Pulse oximeter with wait-time indication
USD736250S1 (en) 2008-06-30 2015-08-11 Covidien Lp Portion of a display panel with an indicator icon
US8968193B2 (en) 2008-09-30 2015-03-03 Covidien Lp System and method for enabling a research mode on physiological monitors
US8211708B2 (en) 2009-03-13 2012-07-03 Furukawa Electric Co., Ltd. Optical measuring device and method therefor
US11369293B2 (en) 2009-07-29 2022-06-28 Masimo Corporation Non-invasive physiological sensor cover
US11779247B2 (en) 2009-07-29 2023-10-10 Masimo Corporation Non-invasive physiological sensor cover
US10478107B2 (en) 2009-07-29 2019-11-19 Masimo Corporation Non-invasive physiological sensor cover
US11559227B2 (en) 2009-07-29 2023-01-24 Masimo Corporation Non-invasive physiological sensor cover
US10588556B2 (en) 2009-07-29 2020-03-17 Masimo Corporation Non-invasive physiological sensor cover
US9380969B2 (en) 2009-07-30 2016-07-05 Covidien Lp Systems and methods for varying a sampling rate of a signal
US9839381B1 (en) 2009-11-24 2017-12-12 Cercacor Laboratories, Inc. Physiological measurement system with automatic wavelength adjustment
US11534087B2 (en) 2009-11-24 2022-12-27 Cercacor Laboratories, Inc. Physiological measurement system with automatic wavelength adjustment
US10750983B2 (en) 2009-11-24 2020-08-25 Cercacor Laboratories, Inc. Physiological measurement system with automatic wavelength adjustment
US11571152B2 (en) 2009-12-04 2023-02-07 Masimo Corporation Calibration for multi-stage physiological monitors
US10729402B2 (en) 2009-12-04 2020-08-04 Masimo Corporation Calibration for multi-stage physiological monitors
US8761854B2 (en) 2010-04-30 2014-06-24 Coviden Lp Method for respiration rate and blood pressure alarm management
US8930145B2 (en) 2010-07-28 2015-01-06 Covidien Lp Light focusing continuous wave photoacoustic spectroscopy and its applications to patient monitoring
US8521246B2 (en) 2010-07-29 2013-08-27 Covidien Lp Cable cross talk suppression
US10092193B2 (en) 2012-02-24 2018-10-09 Covidien Lp Hypovolemia diagnosis technique
US11478155B2 (en) 2012-02-24 2022-10-25 Covidien Lp Hypovolemia diagnosis technique
US9833146B2 (en) 2012-04-17 2017-12-05 Covidien Lp Surgical system and method of use of the same
US9462976B2 (en) 2012-12-22 2016-10-11 Covidien Lp Methods and systems for determining a probe-off condition in a medical device
US8922788B2 (en) 2012-12-22 2014-12-30 Covidien Lp Methods and systems for determining a probe-off condition in a medical device
US9560995B2 (en) 2013-02-25 2017-02-07 Covidien Lp Methods and systems for determining a probe-off condition in a medical device
US11160464B2 (en) 2013-08-23 2021-11-02 Covidien Lp Systems and methods for monitoring blood pressure
US10226188B2 (en) 2013-08-23 2019-03-12 Covidien Lp Systems and methods for monitoring blood pressure
US10383579B2 (en) 2014-10-16 2019-08-20 Covidien Lp System and method for monitoring autoregulation
WO2016178119A1 (en) * 2015-04-27 2016-11-10 LifeWatch Technologies, Ltd. Positioning a medical device based on oxygen saturation measurements
US10219705B2 (en) 2015-05-08 2019-03-05 Covidien Lp System and method for identifying autoregulation zones
US10194870B2 (en) 2015-05-27 2019-02-05 Covidien Lp Systems and methods for optimizing autoregulation measurements
US10932724B2 (en) 2015-06-17 2021-03-02 Covidien Lp Systems and methods for monitoring autoregulation using a confidence level
US10271779B2 (en) 2015-06-30 2019-04-30 Covidien Lp System and method of monitoring autoregulation
US10292663B2 (en) 2015-06-30 2019-05-21 Covidien Lp System and method of monitoring autoregulation
US11096588B2 (en) 2015-10-06 2021-08-24 Covidien Lp System and method for monitoring autoregulation utilizing normalized regional oxygen saturation values
US10463292B2 (en) 2015-10-16 2019-11-05 Covidien Lp System and method for identifying autoregulation zones
US10499818B2 (en) 2015-10-19 2019-12-10 Covidien Lp System and method for providing blood pressure safe zone indication during autoregulation monitoring
US11653840B2 (en) 2015-10-19 2023-05-23 Covidien Lp System and method for providing blood pressure safe zone indication during autoregulation monitoring
US10736578B2 (en) 2016-07-14 2020-08-11 Covidien Lp Systems and methods of monitoring autoregulation
US11419506B2 (en) 2016-08-22 2022-08-23 Covidien Lp System and method for identifying blood pressure zones during autoregulation monitoring

Also Published As

Publication number Publication date
CA2283860A1 (en) 1998-10-01
EP0966665A1 (en) 1999-12-29
JP2001517128A (en) 2001-10-02
AU2105297A (en) 1998-10-20
AU736060B2 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
AU736060B2 (en) Method and apparatus for arbitrating to obtain best estimates for blood constituent values and rejecting harmonics
CA2283858C (en) Method and apparatus for adaptively averaging data signals
US7016715B2 (en) Selection of preset filter parameters based on signal quality
US9351674B2 (en) Method for enhancing pulse oximetry calculations in the presence of correlated artifacts
EP2260758B1 (en) Selection of ensemble averaging weights for a pulse oximeter based on signal quality metrics
US6094592A (en) Methods and apparatus for estimating a physiological parameter using transforms
US7865224B2 (en) Method and apparatus for estimating a physiological parameter
EP1006864A1 (en) Method and apparatus for harmonically filtering data
AU720609B2 (en) Method and apparatus for measuring pulse rate and saturation
AU720238C (en) Method and apparatus for harmonically filtering data

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2283860

Country of ref document: CA

Ref country code: CA

Ref document number: 2283860

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 543256

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997906323

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997906323

Country of ref document: EP